LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 12, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) announced today that for the period of September 12, 2016 to March 10, 2017 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

Laboratory Corporation of America® Holdings Successfully Completes Acquisition of Sequenom, Inc.

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 7, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the successful completion of the offering period for the cash tender offer by its direct wholly owned subsidiary, Savoy Acquisition Corp.

LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 6, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference . LabCorp’s presentation is planned for Monday, September 12, 2016 at 10:30 AM (ET) .

LabCorp’s Acquisition of Sequenom Clears Antitrust Review

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 23, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to the acquisition of Sequenom, Inc.

LabCorp Commences Cash Tender Offer for All Outstanding Shares of Sequenom, Inc.

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 9, 2016-- Laboratory Corporation of America® Holdings (NYSE: LH) today announced the commencement of its cash tender offer for all outstanding shares of the common stock of Sequenom, Inc. (NASDAQ: SQNM) for $2.40 per share.

LabCorp Announces the Availability of the CDC Zika MAC-ELISA Test

The CDC Zika MAC-ELISA Test Has Received FDA Emergency Use Authorization and Complements the RealStar ® Zika Virus RT-PCR Kit U.S. BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 2, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced the nationwide availability of

LabCorp Announces Agreement to Acquire Sequenom

Acquisition Creates Market Leader in NIPT, Women’s Health and Reproductive Genetics LabCorp CEO: ‘This is exactly the kind of strategic acquisition that LabCorp seeks’ BURLINGTON, N.C. & SAN DIEGO --(BUSINESS WIRE)--Jul. 27, 2016-- Laboratory Corporation of America®   Holdings (LabCorp®)

Laboratory Corporation of America® Holdings Announces 2016 Second Quarter Results and Raises 2016 Guidance

Q2 Net revenue of $2.4 billion , up 7% over last year Q2 Diluted EPS of $1.91 ; Q2 Adjusted EPS of $2.31 , up 11% over last year 2016 Adjusted EPS guidance raised to $8.60 – $8.95 , up 9% to 13% over 2015 BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 27, 2016-- Laboratory Corporation of America ®

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 1, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Announces Launch of New Companion Diagnostic for Non-Small Cell Lung Cancer

The Roche cobas ® EGFR Mutation Test v2 is the First Blood-Based Liquid Biopsy Test Approved by FDA for Clinical Use BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 27, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of a new application for the